Abstract
INTRODUCTION
Pulmonary embolism (PE) is the third most lethal cardiovascular disease with an overall risk of death of 15-20% within the first 90 days [1, 2] . The most critical cases of PE with severe circulatory impairment have a mortality within the first hour of up to 70% [3, 4] .
PE is classified, according to the European Society of Cardiology (ESC), into three main categories based on mortality risks: high-, intermediate-and low-risk [5] . High-risk PE patients are characterized by hemodynamic instability or circulatory shock, and intermediate-risk by echocardiographic signs of hemodynamic impairment and/or elevated biochemical cardiac markers (i.e. elevated cardiac troponin I or T concentrations in plasma) in the absence of overt hemodynamic instability. PE patients without clinical, echocardiographic or biochemical signs of hemodynamic impairment are classified as low-risk [5] .
It is recommended by both the ESC and the American Heart Association that high-risk PE patients undergo active treatment to resolve or remove the PE clot [5, 6] . A recent meta-analysis has shown that active lysis of the PE clot by intravenous thrombolysis reduces 30-day mortality by 47% [7] . The risk of life-threatening haemorrhage associated with thrombolysis is nearly doubled compared to heparin treatment alone [7] . Surgical embolectomy is recommended when thrombolysis is contraindicated or instantaneous clot removal is warranted. This treatment is normally reserved to PE patients with severe hemodynamic compromise, and despite the patients critical status studies have shown a 30-day mortality as low as 7-8% [5, [8] [9] [10] [11] .
In contrast to short-term mortality after surgical embolectomy and thrombolysis the long-term mortality, functional capacity and morbidity after treatment are largely undescribed [7] [8] [9] [10] 12] .
The aims of this study were to examine the long-term mortality and morbidity after thrombolysis and surgical embolectomy for acute PE. Special emphasis has been placed on ventilation/ perfusion mismatch by single-photon emission computed tomography in combination with X-ray computed tomography (SPECT-CT), pulmonary diffusion impairment and echocardiographic parameters.
MATERIALS AND METHODS

Study design
The study is designed as a longitudinal cohort study with prospective follow-up of mortality and morbidity after acute PE.
Patients
Patients treated with surgical embolectomy from September 1998 through 2014 and patients treated with thrombolysis from January 2008 through 2014 at the Departments of Cardiothoracic Surgery and Cardiology, Copenhagen University Hospital Rigshospitalet, Denmark were included. Patients were identified in the departments' diagnostic database (Grøntsystem V R , CSC Scandihealth, Aarhus, Denmark) and the surgical registry (PATS V R , Axis Clinical Software Inc., Portland, OR, USA).
All high-risk PE patients had a documented systolic blood pressure lower than 90 mmHg or a systolic blood pressure drop of 40 mmHg for at least 15 min at the time of diagnosis as defined in the ESC guidelines.
The intermediate-risk PE patients underwent active treatment with surgical embolectomy or thrombolysis either due to intra cardiac pathology (thrombus trapped in persistent foramen ovale or intra cardiac thrombi) or severe respiratory symptoms and large thrombi load on CT scanning but without a systolic blood pressure drop.
If patients had been unsuccessfully treated with thrombolysis and thereafter referred to salvage surgical embolectomy they were included in the surgical study cohort as this is representative for the clinical setting.
Mortality within 5 years from treatment was registered and eligible patients were scheduled to an outpatient follow-up visit including clinical interview, cardiac and pulmonary function tests as described below. A minimum period of 3 months from PE treatment to participation in the follow-up visit was required.
Pulmonary function tests
Dynamic and static spirometry with body plethysmography and diffusion capacity for carbon monoxide measurements and if indicated reversibility tests were performed [13] . Diffusion impairment was indexed according to expected value by age, sex, height and corrected for haemoglobin and classified in (i) Mild diffusion impairment: < lower limit of normal and > 60% predicted value, (ii) Moderate diffusion impairment: 40-60% of predicted value and (iii) Severe diffusion impairment: < 40% of predicted value.
SPECT-CT was performed using inhalation and intravenously injection of 81m Kr and 99m Tc-MAA, respectively [14] . All scans were evaluated by two reviewers blinded for clinical data with assessment of number of pulmonary segments with ventilation/ perfusion mismatch indicating residual emboli. Perfusion mismatches were grouped into three categories (Group I: 1-3 segments, Group II: 4-6 segments and Group III: 7-10 segments).
The same experienced lab technician performed 6-min walk test (6-MWT) with registration of walking distance, Borg's dyspnoea index, pulse and saturation changes according to the guidelines from the American Thoracic Society [15, 16] .
Cardiac function tests
Transthoracic echocardiography (TTE), performed by a European Association of Cardiovascular Imaging certified laboratory with special emphasis on the right side of the heart was performed. Measurements included peak tricuspid regurgitation gradient (TRG), right ventricle (RV) size, tricuspid annulus plane systolic excursion (TAPSE) and tricuspid insufficiency. TRG values larger than 35 mmHg and TAPSE values lower than 1.8 cm were classified as abnormal. RV diastolic diameter larger than 33 mm was classified as enlarged, and divided into mild (34-37 mm), moderate (38-41 mm) and severe (>41 mm) enlargement [17] .
The study was approved by the Danish National Committee on Health Research Ethics (ID number: H-2-2012-013) and the Danish Data Protection Agency (ID number: 2007-58-0015.) All patients signed a written consent before participating in the study.
Treatment
Surgical embolectomy was performed with median sternotomy, standard central cannulation and cardiopulmonary bypass (CPB) in normothermia. The main pulmonary artery was opened and thrombus was retrieved with suction and in some cases Forgarty balloon catheter. If intra-cardial access was needed CPB was performed with bicaval cannulation, the aorta cross clamped and the heart arrested with cardioplegia. No patients had vena cava filters inserted.
Patients receiving thrombolysis were treated with Reteplase 10 U administered intravenously two times with 30 min interval. In case of rethrombolysis, the same algorithm was used.
All patients were treated with anticoagulation after the PE event with low-molecular weight heparin and warfarin for a minimum of 6 months. In case of active cancer disease, low-molecular weight heparin was continued for the duration of the planned treatment and no warfarin was given.
Statistics
All data were processed in SPSSV C version 22 (IBM Corporation, New York, USA) statistical program. Data are presented as mean with standard deviation (SD) or median with range [lowest value-highest value] depending on data distribution. Differences between groups were calculated with the Students T-Test, MannWhitney U-test or Chi Square test depending on data type. Correlations were calculated using regression analysis. Mortality was analysed using Kaplan-Meyer plots with censoring at the time when patients had participated in the follow-up visit. Differences in mortality were calculated with the Log Rank (Mantel-Cox) test and odds ratios (OR) with logistic regression. Clinical variables defining the severity of the PE disease together with age, sex and treatment were selected as covariates in the regression model.
RESULTS
Study population
A total of 149 patients ( Fig. 1 ) received thrombolysis or surgical embolectomy for high-or intermediate-risk PE in the study period. Eight patients declined study participation or did not respond to follow-up invitations and 5 patients were excluded due to new incidents of acute PE after their index PE treatment with thrombolysis or surgical embolectomy.
The study population consisted of 136 patients ( Fig. 1 ) with 16 patients declining participation in the follow-up visit but gave health information, and had no signs of chronic dyspnoea or signs of heart failure. These 16 patients (5 high-risk PE and 11 intermediate-risk PE) were included in the mortality analysis. In the remaining group of 120 patients, 40 were deceased (25 highrisk PE and 15 intermediate-risk PE) and 80 (85%) participated in the follow-up visit (34 high-risk and 46 intermediate-risk).
The median time from PE event to follow-up visit was for high-risk PE patients 31 months in both treatment groups. For the intermediate-risk PE patients, the median follow-up time was 135 months for patients treated with surgery and 27 months for patients treated with thrombolysis (P = 0.001). The difference was caused by 6 patients treated with surgery having more than 10 years between treatment and follow-up.
Background data on the study population are shown in Table 1 . Patients with high-risk PE and treated with surgical embolectomy had a longer admission to both the cardiac intensive care unit and the cardiac unit than patients treated with thrombolysis.
Multivariate mortality analysis was done for the whole study population with baseline parameters from the PE event (Table 2) . Dyspnoea and unconsciousness during the PE event were significant risk factors for long-term mortality (Table 2 ) and unconsciousness for 30-day mortality with a OR of 31.3 (P = 0.01).
High-risk pulmonary embolism patients
High-risk PE patients had an overall 30-day mortality of 23% ( Fig.  2A ) with 4 deaths (14%) in the group treated with surgical embolectomy compared to 11 (31%) in the group treated with thrombolysis (P = 0.16). The 5-year mortality analysis (Fig. 2B) showed a mortality of 36% comprised of 9 (32%) deaths in patients treated with surgical embolectomy and 14 (49%) treated with thrombolysis (P = 0.53).
Pulmonary function tests
In 20 (59%) out of 34 patients with high-risk PE, SPECT-CT scan revealed ventilation/perfusion mismatch indicating residual emboli (Table 3) . Patients treated with surgical embolectomy had a significant lower incidence of residual emboli [4 cases (31%)] as compared to patients treated with thrombolysis [16 cases (76%)], (P = 0.009).
Pulmonary diffusion test revealed 19 (56%) high-risk PE patients with signs of pulmonary diffusion impairment (Table 3) . Four (31%) of these patients were treated with surgery and 15 (71%) with thrombolysis (P = 0.02).
Further analysis revealed that patients with pulmonary diffusion impairment were significantly overrepresented in the group having ventilation/perfusion mismatch with 14 patients having both diffusion impairment and ventilation/perfusion mismatch compared to 5 patients with diffusion impairment alone (P = 0.049).
Spirometry did not reveal any signs of pulmonary disease in the high-risk PE population.
High-risk PE patients treated with surgical embolectomy had a mean 6-MWT distance of 527 metres compared to 457 metre in patients treated with thrombolysis (P = 0.04) ( Table 3) . No significant difference in the 6-MWT was observed when adjusted for the age difference between the two groups (P = 0.17).
Echocardiographic data
TRG measured with TTE was obtained in 31 patients with high-risk PE and was larger than 35 mmHg in 3 (17%) patients treated with thrombolysis (Table 3) . RV dilation (larger than 33 mm) was found in 14 patients with 9 (69%) in the surgical treated group in respect to 5 (24%) in the group treated with thrombolysis (P = 0.009). This difference was primarily found between the groups with mild (34-37 mm) enlargement (Table 3) . TAPSE was lower than 1.8 cm in two patients (6%), one from each treatment group.
Intermediate-risk PE patients
Only one patient treated with thrombolysis died within the first 30-days and the 5-year mortality were similar between the two treatment groups (P = 0.86) (Fig. 3) . The results from the follow- 
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up visit did not show any significant differences between surgical embolectomy and thrombolysis in respect to ventilation/perfusion mismatch, pulmonary diffusion impairment, spirometry (one patient treated with surgery had obstructive pulmonary disease and two patients treated with thrombolysis had restrictive pulmonary disease) or 6-MWT (Table 4) . However, the NYHA (New York Heart Association) classification for patients treated with thrombolysis was significantly lower than for surgical treated patients. RV enlargement was demonstrated on TTE (diastolic RV size > 33 mm) in 8 (73%) patients in the surgical embolectomy group as compared to 13 (37%) patients treated with thrombolysis (P = 0.05) ( Table 4) . No significant difference between treatment groups was found for RV function.
DISCUSSION
The overall 30-day mortality for high-risk PE patients in this study was 23% with no difference between patients treated with surgical embolectomy or thrombolysis. Similar short-term survival data have been observed in other studies and have been implemented in the ESC guidelines as the expected mortality for highrisk PE patients [5, 18] .
Our data revealed a similar 5-year mortality for patients treated with surgical embolectomy compared to thrombolysis in both the high-(14% for surgical embolectomy and 32% for thrombolysis) and intermediate-risk (23% for surgical embolectomy and 16% for thrombolysis) PE group.
In a retrospective study from Switzerland, the authors described the long-term mortality in 80 patients presenting with massive PE. Of these, 28 were treated with surgical embolectomy and 52 with thrombolysis [19] . The 5-year mortality was 20% in both treatment groups. The classification of PE was based on the amount of central clot burden or circulatory impairment and not strictly according to the ESC guidelines. This may explain the lower 5-year mortality rate compared to our findings. It is noticeable that the patients in the Swiss study treated with surgical embolectomy had a significantly higher pulmonary pressure, larger RVs and higher NYHA classifications at baseline than the patients treated with thrombolysis [19] .
In similarity with our observations, short-and long-term survival in 115 surgically treated high-or intermediate-risk PE patients have been described in a recently published study [20] . The 5-year mortality was found to be 40% for high-risk and 20% for intermediate-risk PE patients. The authors recommend that intermediate-risk PE patients with imminent risk of haemodynamic decompensation due to severe RV impairment and central clot burden should be evaluated for surgical treatment [20] .
It appears that surgical embolectomy although normally confined to the most critical PE patients can be done with good long-term survival comparable to active medical treatment with thrombolysis despite the mortality risk inflicted by the surgical procedure.
Interestingly, the present study identified high-risk PE patients treated with surgical embolectomy had a significantly lower amount of residual emboli and pulmonary diffusion impairment than patients treated with thrombolysis. This observation has not been described before, and could have a major impact on the decision of optimal medical or surgical treatment of acute high-risk PE.
The clinical consequences of residual emboli after PE have been investigated in 254 consecutive patients with acute all type PE. Residual emboli were identified in 73 patients having a significant shorter 6-MWT, a higher mean pulmonary arterial pressure and more dyspnoea when compared to PE patients without residual emboli [21] . The importance of residual emboli reduction is further emphasized in a study by Meneveau et al. who described residual clot burden to be an independent risk factor for increased mortality at long-term follow-up in 227 high-or intermediate-risk PE patients [22] . Furthermore, residual emboli after acute PE was found to be an independent predictor for Chronic Thromboembolic Pulmonal Hypertension a severe late complication of acute PE [21, 23] . Pulmonary diffusion impairment after acute PE occurred more frequently in high-risk patients treated with thrombolysis compared to surgical embolectomy and was correlated with residual emboli. Similar observations have been made in a small study with 20 patients. In this study, a reduced pulmonary diffusion below 75% of the predicted normal value was found in all patients with abnormal lung scans at time of the PE event. The reduction in pulmonary diffusion persisted in the follow-up period of up to 3 years despite the lung scans normalized [24] .
Our data did not identify any relationship between abnormal spirometry and signs of residual emboli. Based on our study, spirometry cannot be used as a screening tool for morbidity after acute PE.
It seems that treatment of acute PE should focus on achieving maximal clot removal to avoid residual emboli and pulmonary impairment. The surgical superiority on pulmonary morbidity may rely on rapid removal of the total emboli resulting in fast restoration of normal pulmonary circulation where thrombolysis either is unable to resolve the emboli due to its size or fractionates it into smaller parts which are carried to the periphery of the pulmonary vasculature. However, the surgical superiority could not be demonstrated in the intermediate-risk PE population. It might be speculated that thrombus material has a more peripheral location in intermediate-risk PE patients and is less accessible for surgical removal.
Cardiac examination revealed that significant more PE patients treated with surgical embolectomy had enlarged RVs compared to patients treated with thrombolysis. The enlargement was mild and was not correlated to decreased RV function or elevated pulmonary pressures.
Differences in cardiac outcome after surgical embolectomy and thrombolysis for PE have been described by Azari et al.
Patients with high-risk PE, 30 of which were treated with surgical embolectomy and 78 with thrombolysis. At one-year follow-up, the surgical treated patients had a higher decrease in pulmonary pressure, RV diameter and NYHA class than patients treated with thrombolysis [25] .
Limitations
The study is limited by its retrospective observational nature and the limited knowledge of baseline clinical data from the time of treatment for comparison. However, by close scrutiny of several administrative registries it appears that the study sample represents consecutive cases. Eighty five percent of the patients eligible for follow-up visit participated. To minimize this bias, the remaining 15% (16 patients) which did not participate in the follow-up visit reported health information by phone or mail with no cardiac or pulmonary symptoms identified.
The inclusion timeframe for surgical treated patients was longer to obtain a reasonable number of patients, and there was no fixed time point for the follow-up visit after treatment other than a minimum of 3 months after the PE treatment.
Finally, follow-up information on the deceased patients were not available. It should be borne in mind that the largest amount of residual emboli and pulmonary diffusion impairment could potentially occur in this subgroup of patients
CONCLUSIONS
In this study, surgical embolectomy for acute high-risk PE is found to have a better outcome on pulmonary end-points and similar short-and long-term survival compared to thrombolysis.
Surgical embolectomy remains a pivotal treatment option for significant acute PE. Patients with high-risk and possible severe intermediate-risk acute PE may benefit from being referred to centres with expertise in advanced cardiology and cardiothoracic surgery for interdisciplinary evaluation of the optimal treatment strategy.
